Goldman Sachs
SLXP

Goldman Sachs’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Goldman Sachs’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,733,556
Closed -$300M – 7688
2015
Q1 		$300M Buy
1,733,556
+611,026
+54% +$89.7M 0.1% 213
2014
Q4 		$129M Buy
1,122,530
+236,813
+27% +$28.7M 0.04% 556
2014
Q3 		$138M Buy
885,717
+396,345
+81% +$57.5M 0.04% 491
2014
Q2 		$60.4M Buy
489,372
+199,997
+69% +$22.1M 0.02% 962
2014
Q1 		$30M Buy
289,375
+176,801
+157% +$18.1M 0.01% 1431
2013
Q4 		$10.1M Sell
112,574
-30,839
-22% -$2.46M ﹤0.01% 2350
2013
Q3 		$9.59M Buy
143,413
+33,075
+30% +$2.28M ﹤0.01% 2299
2013
Q2 		$7.3M Buy
+110,338
New +$6.31M ﹤0.01% 2365

Other funds holding SLXP

MMG
Monetary Management Group St Louis, Missouri $487M AUM 49.37% 1-Year Est. Return

Goldman Sachs's SLXP Position: Q2 2015 in Review

Goldman Sachs sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q2 2015, closing a stake of 1,733,556 shares — an estimated $300M sold.

Goldman Sachs first reported a position in SLXP in Q2 2013 and held it in 8 quarters. The position peaked at $300M in Q1 2015. 1 fund tracked by Wall St. Rank holds SLXP as of Q2 2015.

  • Goldman Sachs reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q2 2015 after selling out during the quarter.
  • Goldman Sachs sold 1,733,556 SALIX PHARMACEUTICALS LTD DEL shares in Q2 2015, an estimated $300M.
  • Goldman Sachs first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 8 quarters.
  • Goldman Sachs's SALIX PHARMACEUTICALS LTD DEL position peaked at $300M in Q1 2015.
  • 1 fund tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q2 2015.

Based on Goldman Sachs's 13F filing for Q2 2015, filed 14 Aug 2015.